Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Invasive Breast Cancer × pertuzumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 141 HER2-positive Breast Cancer 15 Neoplasms 11 Neoplasm Metastasis 8 Carcinoma, Non-Small-Cell Lung 6 Prostatic Neoplasms 5 Ovarian Neoplasms 5 Stomach Neoplasms 4 Inflammatory Breast Neoplasms 4 Colonic Neoplasms 4 Brain Neoplasms 4 Triple Negative Breast Neoplasms 3 Solid Tumor 3 Pathologic Complete Response 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Endometrial Neoplasms 3 Breast Neoplasms, Male 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Rectal Neoplasms 2 Locally Advanced Breast Cancer 2 Hematologic Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 HER2-positive Early Breast Cancer 2 Gastrointestinal Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Ductal, Breast 2 Anatomic Stage II Breast Cancer AJCC v8 2

Interventions

Trastuzumab 2 Surgical Procedures, Operative 2 Paclitaxel 2 Doxorubicin 2 Cyclophosphamide 2 pertuzumab 1 atezolizumab 1 Radiotherapy 1 Magnetic Resonance Spectroscopy 1 Lapatinib 1 Indocyanine Green 1 Carboplatin 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03595592 2024-03-06

APTneo

Fondazione Michelangelo

Phase 3 Active not recruiting

Invasive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡